Thymoma
60 programs · 60 companies
Programs
60
Companies
60
Trials
55
MOAs
40
HER2PD-L1iAuroraAiKIF18AiEZH2iWEE1iPRMT5iUSP1iJAK1/2iCAR-T CD19
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| TAK-9344 | Phase 3 | CGRP | ||
| Nirafutibatinib | Phase 2 | WRN | ||
| REG-861 | Phase 2 | PARP | ||
| Fixaglumide | Phase 2/3 | WEE1 | ||
| Polalucimab | Preclinical | PLK4 | ||
| Motanaritide | Approved | PD-1 | ||
| Zanurapivir | Phase 1 | SOS1 | ||
| Tezeratamab | Phase 3 | CGRP | ||
| Voxazasiran | Phase 2/3 | JAK2 | ||
| SAG-8067 | NDA/BLA | PLK4 | ||
| Semarapivir | Phase 2 | FXIa | ||
| Nidarelsin | Phase 2/3 | RET | ||
| Mavulucimab | NDA/BLA | AHR | ||
| 450-5704 | Phase 2/3 | PRMT5 | ||
| Sovaglumide | Phase 3 | PCSK9 | ||
| MAY-IIT-189 | Approved | TNFα | ||
| NIA-IIT-954 | Phase 2 | PSMA | ||
| STA-IIT-824 | Phase 1/2 | RET | ||
| UCS-IIT-265 | Phase 3 | AHR | ||
| MIR-8648 | Phase 1/2 | GLP-1R | ||
| HOR-3601 | Phase 1/2 | FXIa | ||
| Surafotisoran | Phase 2 | APOC3 | ||
| GRT-6331 | NDA/BLA | TROP-2 | ||
| ENT-2952 | Phase 3 | JAK2 | ||
| Polatuximab | Phase 1/2 | TROP-2 | ||
| COR-4726 | Preclinical | PRMT5 | ||
| CON-544 | NDA/BLA | TIM-3 | ||
| Cevirasimod | Preclinical | CD19 | ||
| Suraderotide | Phase 1 | TIGIT | ||
| BTA-1886 | Phase 1 | FXIa | ||
| CNT-6977 | Preclinical | SOS1 | ||
| CON-372 | Approved | MALT1 | ||
| 117-9336 | Phase 2/3 | PLK4 | ||
| Olpasotorasib | Phase 1/2 | WRN | ||
| Fixazasiran | Approved | MDM2 | ||
| Doxaderotide | Phase 3 | SMN2 | ||
| TER-8481 | Phase 1/2 | KRASG12C | ||
| NCN-3378 | NDA/BLA | PD-L1 | ||
| Zorisertib | Approved | SHP2 | ||
| Rimacagene | Preclinical | BCL-2 | ||
| GNL-2086 | Preclinical | CD3 | ||
| IST-1205 | Phase 2 | HER2 | ||
| LPC-4508 | Phase 1 | PSMA | ||
| Datotapinarof | Phase 1 | AHR | ||
| 219-3907 | Approved | LAG-3 | ||
| MOR-4433 | Phase 1/2 | GLP-1R | ||
| Olpaderotide | Phase 2 | BTK | ||
| Datorasimod | Phase 2/3 | CDK4/6 | ||
| Polavorutinib | Phase 3 | HER2 | ||
| Lirazumab | Phase 1 | KRASG12D | ||
| Gelizasiran | Phase 2/3 | CDK2 | ||
| Tixasotorasib | Preclinical | BCMA | ||
| MOR-6182 | Phase 1/2 | TNFα | ||
| CHI-IIT-951 | Phase 2 | FcRn | ||
| RUI-IIT-209 | Preclinical | GIP-R | ||
| WST-2406 | Phase 2 | Tau | ||
| Elralucimab | Phase 1/2 | SOS1 | ||
| Polafotisoran | NDA/BLA | TNFα | ||
| VCY-7974 | Phase 1 | CD20 | ||
| Cevisertib | Phase 2/3 | SOS1 |
Trials (55)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06357902 | TAK-9344 | Phase 3 | Active |
| NCT05328704 | Fixaglumide | Phase 2/3 | Completed |
| NCT08728803 | Polalucimab | Preclinical | Not yet recr... |
| NCT08221130 | Motanaritide | Approved | Completed |
| NCT04098504 | Voxazasiran | Phase 2/3 | Not yet recr... |
| NCT03929248 | SAG-8067 | NDA/BLA | Recruiting |
| NCT05436494 | SAG-8067 | NDA/BLA | Completed |
| NCT07234026 | Semarapivir | Phase 2 | Terminated |
| NCT07039311 | Nidarelsin | Phase 2/3 | Active |
| NCT07071228 | 450-5704 | Phase 2/3 | Terminated |
| NCT07848630 | Sovaglumide | Phase 3 | Recruiting |
| NCT04210782 | Sovaglumide | Phase 3 | Terminated |
| NCT08734627 | MAY-IIT-189 | Approved | Terminated |
| NCT07331972 | NIA-IIT-954 | Phase 2 | Recruiting |
| NCT06770637 | STA-IIT-824 | Phase 1/2 | Not yet recr... |
| NCT08193313 | UCS-IIT-265 | Phase 3 | Active |
| NCT05171695 | MIR-8648 | Phase 1/2 | Not yet recr... |
| NCT07851470 | Surafotisoran | Phase 2 | Completed |
| NCT03979891 | ENT-2952 | Phase 3 | Active |
| NCT03128068 | ENT-2952 | Phase 3 | Active |